135 related articles for article (PubMed ID: 33658923)
1. Population Pharmacokinetics of Phosphocreatine and Its Metabolite Creatine in Children With Myocarditis.
He H; Zhang M; Zhao LB; Sun N; Zhang Y; Yuan Y; Wang XL
Front Pharmacol; 2020; 11():574141. PubMed ID: 33658923
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and hemorheology of phosphocreatine and creatine in rabbits: A directly comparative study between parent drug and active metabolite.
Xi H; Zhang A; Han G; Li C; Lv L
Eur J Pharm Sci; 2019 Oct; 138():105033. PubMed ID: 31382031
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of phosphocreatine and its active metabolite creatine in the mouse plasma and myocardium.
Xu L; Wang CY; Lv L; Liu KX; Sun HJ; Han GZ
Pharmacol Rep; 2014 Oct; 66(5):908-14. PubMed ID: 25150000
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats].
Zou LL; Li QS; Han GZ; Lü L; Xi H; Li JH
Yao Xue Xue Bao; 2011 Jan; 46(1):75-80. PubMed ID: 21465812
[TBL] [Abstract][Full Text] [Related]
5. [Simultaneous determination of exogenous phosphocreatine and its metabolite creatine in rabbit plasma using ion-pair reversed-phase high performance liquid chromatography].
Xi H; Han G; Lü L; Zhang D
Se Pu; 2011 Oct; 29(10):1000-4. PubMed ID: 22268357
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantitative analysis of phosphocreatine, creatine and creatinine in plasma of children by HPLC-MS/MS method: Application to a pharmacokinetic study in children with viral myocarditis.
Sun N; Li Q; Zhao L; He H; Zhang M; Wang X
Biomed Chromatogr; 2019 Aug; 33(8):e4558. PubMed ID: 31013362
[TBL] [Abstract][Full Text] [Related]
7. Hydromorphone population pharmacokinetics in pediatric surgical patients.
Balyan R; Dong M; Pilipenko V; Geisler K; Vinks AA; Chidambaran V
Paediatr Anaesth; 2020 Oct; 30(10):1091-1101. PubMed ID: 32702184
[TBL] [Abstract][Full Text] [Related]
8. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
9. Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting.
Chain A; Wrishko R; Vasilinin G; Mouksassi S
J Pediatr Pharmacol Ther; 2020; 25(6):528-539. PubMed ID: 32839657
[TBL] [Abstract][Full Text] [Related]
10. Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling.
Rong Y; Wichart J; Hamiwka L; Kiang TKL
Clin Pharmacokinet; 2023 Sep; 62(9):1289-1303. PubMed ID: 37493886
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients.
Carrothers TJ; Lagraauw HM; Lindbom L; Riccobene TA
Pediatr Infect Dis J; 2023 Feb; 42(2):99-105. PubMed ID: 36638392
[TBL] [Abstract][Full Text] [Related]
13. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
Cheng Y; Xue Y; Chen L; Masin M; Maciag P; Peluso T; Zhou S; Li Y
Br J Clin Pharmacol; 2023 Jan; 89(1):316-329. PubMed ID: 35981078
[TBL] [Abstract][Full Text] [Related]
14. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Edwards AY; Skolnik JM; Dombrowsky E; Patel D; Barrett JS
Cancer Chemother Pharmacol; 2012 Jul; 70(1):83-94. PubMed ID: 22623208
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
[TBL] [Abstract][Full Text] [Related]
16. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
18. The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia.
Cheng X; Zhao Y; Gu H; Zhao L; Zang Y; Wang X; Wu R
Int J Immunopathol Pharmacol; 2020; 34():2058738420934936. PubMed ID: 32720540
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
